Compare CLST & XLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CLST | XLO |
|---|---|---|
| Founded | 1922 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 67.3M | 56.9M |
| IPO Year | 2021 | 2021 |
| Metric | CLST | XLO |
|---|---|---|
| Price | $17.06 | $9.11 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $28.00 |
| AVG Volume (30 Days) | 2.5K | ★ 35.6K |
| Earning Date | 04-30-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 171.79 | N/A |
| EPS | ★ 0.15 | N/A |
| Revenue | N/A | ★ $43,766,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $168.77 |
| P/E Ratio | $111.67 | ★ N/A |
| Revenue Growth | N/A | ★ 589.88 |
| 52 Week Low | $12.40 | $0.46 |
| 52 Week High | $18.16 | $9.89 |
| Indicator | CLST | XLO |
|---|---|---|
| Relative Strength Index (RSI) | 51.84 | 52.87 |
| Support Level | $16.37 | $8.31 |
| Resistance Level | $17.19 | $9.89 |
| Average True Range (ATR) | 0.18 | 0.39 |
| MACD | -0.04 | -0.00 |
| Stochastic Oscillator | 32.73 | 69.35 |
Catalyst Bancorp Inc is a bank holding company. Through its subsidiary, which is a federally chartered community-oriented savings bank, it is engaged in attracting deposits from the general public and using those funds to invest in loans and securities. The sources of funds are customer deposits, repayments of loans, maturities of investments, and funds borrowed from outside sources, which are used for the origination of loans. It operates in one reportable segment, which generates income principally from interest on loans and investment securities, as well as from fees charged in connection with various loan and deposit services.
Xilio Therapeutics Inc is a clinical-stage biotechnology company focused on discovering and developing masked immuno-oncology (I-O) therapies to improve outcomes for people living with cancer. Leveraging its clinically validated masking technology and capabilities, the company develops I-O therapies designed to selectively activate within the tumor microenvironment to achieve durable efficacy without the severe side effects associated with systemically active I-O agents. Its integrated biology and protein engineering approach enables the design and development of potent masked biologics that are activated by tumor-specific proteases.